Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05767736 · ClinicalTrials.gov registry record
A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)
A clinical trial of Multiple Sclerosis, sponsored by Biogen.
- Active
- Registry status
- 10,500
- Enrollment target
- 1
- Study location
NCT05767736: Active study of Multiple Sclerosis, sponsored by Biogen.
NCT05767736 is a study of Multiple Sclerosis that is active but no longer recruiting, run by Biogen. The registered enrollment target is 10,500 participants, above the 552-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (1802% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05767736, a study of Multiple Sclerosis, is active but no longer recruiting, sponsored by Biogen.
- ACTIVE NOT RECRUITING
- Registry status
- 10,500 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of the study is to estimate the incidence rate of serious adverse events (SAEs), including but not limited to malignancies and serious and opportunistic infections, among participants with MS treated with Vumerity, Tecfidera, other selected disease modifying therapies (DMTs \[teriflunomide, beta interferons, or glatiramer acetate\]), or Vumerity after switching from Tecfidera. The secondary objective of the study is to compare the incidence rate of SAEs, including but not limited to malignancies and serious and opportunistic infections, among MS participants treated with Vumerity, Tecfidera, and Vumerity after switching from Tecfidera with the incidence rate of MS participants treated with other selected DMTs (teriflunomide, beta-interferons, or glatiramer acetate), if the sample size allows.
Primary Outcome
An SAE is any untoward medical occurrence that at any dose results in death, in the view of the investigator, places the participant at immediate risk of death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, and results in a congenital anomaly/birth defect. The incidence rate of confirmed SAEs, will include but not be limited to malignancies and serious and opportunistic infections among participants wit
Conditions Studied
Interventions
- DRUG Diroximel Fumarate
- DRUG Dimethyl Fumarate
- DRUG Disease-Modifying Therapies (DMTs)
Study Locations (1)
Massachusetts
- Research Site - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,500 participants |
| Start Date | 2024-06-08 |
| Est. Completion | 2032-12-01 |
What the registry record for NCT05767736 still lists
NCT05767736 is an observational study that tracks outcomes without assigning an intervention. Its 10,500 participants enrollment target places it among the larger protocols in the corpus, above the 552-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (1802% higher).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 3 interventions - of which Diroximel Fumarate is the first listed.
NCT05767736 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05767736 about?
NCT05767736 is a clinical study titled "A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)". The primary objective of the study is to estimate the incidence rate of serious adverse events (SAEs), including but not limited to malignancies and serious and opportunistic infections, among participants with MS treated with Vumerity, Tecfidera, other selected disease modifying therapies (DMTs \[t...
What is the current status of trial NCT05767736?
This trial is currently active not recruiting. The enrollment target is 10,500 participants. The study started on 2024-06-08. Estimated completion is 2032-12-01.
What conditions does trial NCT05767736 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT05767736?
The interventions under investigation include: Diroximel Fumarate (DRUG), Dimethyl Fumarate (DRUG), Disease-Modifying Therapies (DMTs) (DRUG).
Who is sponsoring clinical trial NCT05767736?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05767736 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05767736's enrollment target sits among peer trials
10,500 3rd of 315 higher than 313 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05759299 · 10,500 participants
International obServational sTudy on AiRway manaGement in operAting Room and Non-operaTing Room anaEsthesia
- NCT06891222 · 10,500 participants
A Study of Electrocardiogram and Focused Cardiac Ultrasound for Enhanced Cardiac Disease Screening
- NCT07157774 · 10,450 participants · Phase 3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
- NCT06081517 · 10,600 participants
Evaluating Disparities in Precision Oncology
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI